Sutureless aortic valve replacement in multivalve procedures.
Perceval
Sutureless aortic valve
mitral valve procedure
multivalve procedures
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
02
02
2021
accepted:
02
04
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
ppublish
Résumé
Despite the rapid expansion of transcatheter approaches for aortic valve implantation, surgical aortic valve replacement remains the treatment of choice in patients presenting with multiple valvular heart disease. We sought to review our clinical experience with sutureless aortic valve replacement (SU-AVR) in the setting of multivalve procedures, addressing the postoperative outcomes and technical challenges. Between December 2019 and December 2020, 20 consecutive high-risk patients at our institution underwent SU-AVR and concomitant mitral valve procedure for various indications. The mean age of the patients at operation was 72.6±9.3 years. Fifty five percent of the patients (n=11) presented with moderate to severe symptomatic aortic valve stenosis, while 35% (n=7) suffered from severe aortic regurgitation. All patients had concomitant moderate to severe mitral valve disease, including regurgitation in 95% (n=19) and stenosis in 25% (n=5). Mean logistic EuroSCORE was 34.3%±24.7%. Cardiopulmonary bypass and cross-clamp times were 101 (88.0-123) minutes and 67.5 (51.7-85.2) minutes, respectively. Optimal sutureless aortic valve prosthesis device success was achieved in 20 patients (100%). One patient (5%) required permanent pacemaker implantation. Thirty-day mortality was 10% and no strokes were detected. SU-AVR is a safe and feasible surgical alternative to conventional procedures in patients presenting with multiple valvular heart disease. It provides excellent hemodynamic performance with low risk of paravalvular leakage and low transvalvular gradients, whilst simplifying the surgical procedure. Precise sizing and positioning of the valve prostheses is crucial to ensure optimal postoperative outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Despite the rapid expansion of transcatheter approaches for aortic valve implantation, surgical aortic valve replacement remains the treatment of choice in patients presenting with multiple valvular heart disease. We sought to review our clinical experience with sutureless aortic valve replacement (SU-AVR) in the setting of multivalve procedures, addressing the postoperative outcomes and technical challenges.
METHODS
METHODS
Between December 2019 and December 2020, 20 consecutive high-risk patients at our institution underwent SU-AVR and concomitant mitral valve procedure for various indications.
RESULTS
RESULTS
The mean age of the patients at operation was 72.6±9.3 years. Fifty five percent of the patients (n=11) presented with moderate to severe symptomatic aortic valve stenosis, while 35% (n=7) suffered from severe aortic regurgitation. All patients had concomitant moderate to severe mitral valve disease, including regurgitation in 95% (n=19) and stenosis in 25% (n=5). Mean logistic EuroSCORE was 34.3%±24.7%. Cardiopulmonary bypass and cross-clamp times were 101 (88.0-123) minutes and 67.5 (51.7-85.2) minutes, respectively. Optimal sutureless aortic valve prosthesis device success was achieved in 20 patients (100%). One patient (5%) required permanent pacemaker implantation. Thirty-day mortality was 10% and no strokes were detected.
CONCLUSIONS
CONCLUSIONS
SU-AVR is a safe and feasible surgical alternative to conventional procedures in patients presenting with multiple valvular heart disease. It provides excellent hemodynamic performance with low risk of paravalvular leakage and low transvalvular gradients, whilst simplifying the surgical procedure. Precise sizing and positioning of the valve prostheses is crucial to ensure optimal postoperative outcome.
Identifiants
pubmed: 34277035
doi: 10.21037/jtd-21-300
pii: jtd-13-06-3392
pmc: PMC8264712
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3392-3398Informations de copyright
2021 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-21-300). Alexander Weymann is working as a proctor for LivaNova. The other authors have no conflicts of interest to declare.
Références
Ann Thorac Surg. 2013 Apr;95(4):1383-9
pubmed: 23462264
J Thorac Cardiovasc Surg. 2018 Jun;155(6):2414-2422
pubmed: 29551538
Ann Thorac Surg. 2019 Jul;108(1):99-105
pubmed: 30684479
Eur J Cardiothorac Surg. 2008 Oct;34(4):780-4
pubmed: 18621539
Interact Cardiovasc Thorac Surg. 2014 Jul;19(1):21-6
pubmed: 24722513
J Am Coll Cardiol. 2014 Jun 24;63(24):2643-58
pubmed: 24681140
J Card Surg. 2016 Aug;31(8):476-85
pubmed: 27335256
Circulation. 2005 Aug 30;112(9 Suppl):I443-7
pubmed: 16159860
Ann Thorac Surg. 2018 Jan;105(1):40-46
pubmed: 28964415
Thorac Cardiovasc Surg. 2020 Oct;68(7):602-607
pubmed: 31003238
J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23
pubmed: 23084102
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1354-9
pubmed: 25260274
World J Cardiol. 2018 Sep 26;10(9):119-122
pubmed: 30344959
Ann Thorac Surg. 2017 Jan;103(1):139-144
pubmed: 27544288
Eur J Cardiothorac Surg. 2016 Mar;49(3):709-18
pubmed: 26516193